Using Sensitivity Analyses to Address Unmeasured Confounding and Bias In the rapidly evolving landscape of pharmaceuticals and medical technology, the reliance on real-world data (RWD) is becoming increasingly prominent. As regulatory agencies like the US FDA embrace these data sources, it is essential for professionals in the domain to grasp the nuances of real world data quality integrity bias management. One fundamental aspect of ensuring the robustness of conclusions drawn from RWD is the implementation of sensitivity analyses. This tutorial provides a comprehensive step-by-step approach to integrating sensitivity analyses in order to address unmeasured confounding and bias in RWD. Understanding…

Governance models for RWD quality review boards and data stewards Governance Models for RWD Quality Review Boards and Data Stewards In the evolving landscape of healthcare and life sciences, the importance of real-world data (RWD) has become increasingly crucial for regulatory submissions and decision-making processes. Governance models for RWD quality review boards and data stewards play a fundamental role in ensuring the integrity and quality of real-world data quality integrity bias management. This comprehensive tutorial will guide you through the various aspects of establishing effective governance models for RWD, focusing on RWD fitness for purpose and the management of selection…

Provenance, Lineage and Traceability Controls for Complex RWD Pipelines Real-world data (RWD) plays a pivotal role in the regulatory landscape by providing insights that can influence clinical and regulatory decisions. However, harnessing RWD presents unique challenges related to quality, integrity, and bias management. This article serves as a comprehensive guide to understanding provenance, lineage, and traceability controls within complex RWD pipelines, ensuring they meet the rigorous standards expected by FDA guidance. Understanding Real-World Data and Its Importance Real-world data refers to information collected outside of traditional clinical trials, derived from various sources including electronic health records (EHRs), patient registries, claims…

Future Directions in Standards for RWD Quality and Audit Frameworks The evolving landscape of real-world data (RWD) is significantly impacting the pharmaceutical and medical device sectors. Regulatory, biostatistics, and health economics professionals must comprehend the intricacies of RWD quality, integrity, and bias management to navigate this complex terrain effectively. This tutorial offers a comprehensive overview of future directions in standards for RWD quality and audit frameworks, aiming to equip professionals in the pharma and medtech industries with essential insights and actionable guidance. Understanding Real-World Data (RWD) and Its Importance Real-world data refers to data relating to patient health status and…

KPIs and Dashboards to Monitor Ongoing RWD Quality Performance In recent years, the significance of real-world data (RWD) has escalated in the pharmaceutical and medical devices sectors, particularly with the increasing focus on real-world evidence (RWE) in regulatory submissions. Consequently, ensuring the quality, integrity, and bias management of RWD is paramount for making sound regulatory decisions. This guide provides a comprehensive overview of the key performance indicators (KPIs) and dashboards needed to effectively monitor the ongoing performance of RWD quality. Understanding the Importance of RWD Quality RWD encompasses a variety of data types, including electronic health records (EHRs), medical claims…

Training RWE Teams on Bias Concepts and Causal Inference Fundamentals Introduction to Real World Data (RWD) Quality and Integrity As the utilization of Real World Data (RWD) becomes indispensable in pharmaceutical and medtech sectors, understanding its quality and integrity is paramount. RWD refers to the data relating to patient health, healthcare delivery, and outcomes derived from various sources outside traditional clinical trials. The effectiveness of RWD hinges on its quality, derived primarily from accuracy, completeness, and fitness for purpose. A significant aspect of maintaining high standards in RWD quality integrity bias management involves addressing potential biases in data collection and…

Automation and AI Tools for Anomaly Detection in Large RWD Assets As regulatory, biostatistics, Health Economics and Outcomes Research (HEOR), and Real-World Evidence (RWE) professionals engage with large datasets, it is imperative to understand and ensure the quality, integrity, and bias management of Real-World Data (RWD). In this tutorial, we will explore the step-by-step application of automation and Artificial Intelligence (AI) tools for anomaly detection in large RWD assets. We emphasize the need for rigorous data governance to address issues like selection bias, misclassification, and data provenance, ultimately enhancing the RWD fitness for purpose within the regulatory framework. Step 1:…

Documentation Practices that Demonstrate RWD Quality to Regulators In the ever-evolving landscape of healthcare, the significance of Real-World Data (RWD) has grown dramatically, especially in supporting regulatory decision-making. The U.S. Food and Drug Administration (FDA) emphasizes the imperative for high-quality RWD to ensure that the evidence generated is reliable, valid, and applicable. This guide provides a comprehensive overview of the documentation practices that can demonstrate the quality, integrity, and management of bias in RWD, essential for regulatory professionals, biostatisticians, and others engaged in health economics and outcomes research (HEOR). Understanding RWD and Its Regulatory Importance Real-world data can be defined…

Case Studies Where RWE Shifted HTA and Reimbursement Outcomes Introduction to Real-World Evidence in HTA and Reimbursement Real-world evidence (RWE) has increasingly become a vital component in navigating the healthcare landscape, particularly regarding Health Technology Assessment (HTA) and reimbursement decisions. Endorsed by regulatory bodies such as the FDA, RWE plays a crucial role in detailing the effectiveness of interventions in real-world settings. This article emphasizes the importance of integrating RWE into regulatory strategy and highlights case studies where RWE has shifted HTA and reimbursement outcomes. As the pharmaceutical and biotechnology industries evolve, understanding how RWE can influence healthcare payer decisions…

Designing RWE that Answers Both FDA and Payer Evidence Needs As regulatory landscapes evolve, the integration of Real-World Evidence (RWE) into regulatory strategy and Health Technology Assessment (HTA) discussions has become paramount for pharmaceutical and medical technology companies. This tutorial serves as a comprehensive guide for professionals in regulatory affairs, biostatistics, Health Economics and Outcomes Research (HEOR), and related fields, detailing how to structure RWE to meet the needs of both the FDA and payers effectively. This article provides a step-by-step methodology for aligning integrated evidence plans with regulatory expectations and payer requirements. Understanding the Regulatory Landscape for RWE The…